JMP Securities Reiterates Market Outperform on Bicycle Therapeutics, Maintains $44 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Reni Benjamin has reiterated a Market Outperform rating on Bicycle Therapeutics (NASDAQ:BCYC) and maintained a $44 price target.
September 12, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities has reiterated a Market Outperform rating on Bicycle Therapeutics and maintained a $44 price target.
The reiteration of a Market Outperform rating by JMP Securities indicates a positive outlook for Bicycle Therapeutics. The maintained price target of $44 suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward price movement in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100